ResApp has announced the positive results from its ‘Australian Breathe Easy adult perspective’ clinical study.
ResApp uses a mobile app to diagnose and measure the severity of a range of chronic and acute diseases simply from the information gained by the patients coughing into their phone.
Its algorithms were found to accurately diagnose a range of diseases from pneumonia, asthma, lower respiratory tract disease and chronic obstructive pulmonary disease (COPD).
More than 950 people were tested and evaluated using positive percent agreement (PPA) and negative percent agreement (NPA). These were then compared to a full examination and diagnosis reached by expert clinicians.
With around 339 million people suffering asthma ResApp’s algorithms achieved an 89 percent PPA and an 84 percent NPA when compared to traditional diagnosis.
While asthma and COPD cannot be cured much hope that this app will provide an early diagnosis. CEO Tony Keating hopes these results will get more people using the app.
“These results underpin the commercialisation of a range of smartphone-based acute diagnostic and chronic disease management tools, and we intend to use this data to support CE and TGA regulatory submissions,” he said.